冠心病介入治疗患者个体化抗血小板治疗的研究进展

Research Progress of Individualized Antiplatelet Therapy in Coronary Intervention Patients

血栓是冠心病介入治疗的常见并发症,一旦发生血栓会降低疗效,不利于患者预后恢复。个性化治疗能够在抗血小板的同时降低患者存在的药物抵抗,降低不良反应发生率。替格瑞洛、吲哚布芬、利伐沙班属于新型抗血小板药物,能够有效抑制血栓的形成,具有较高的应用安全性。在对冠心病介入患者进行治疗时,需要综合评价患者的个体状况,并积极分析病情特点,形成现代化的管理体系与优化方案,保障患者的用药治疗安全性。

Thrombus is a common complication of coronary intervention,and once thrombus occurs,it will reduce the efficacy of treatment and is not conducive to the patient's prognosis of recovery.Individualized treatment can reduce the drug resistance existing in patients while antiplatelet and reduce the incidence of adverse reactions.Tegretol,indobufen,and rivaroxaban are new antiplatelet drugs that can effectively inhibit thrombosis and have a high degree of safety.In the treatment of patients with coronary heart disease intervention,it is necessary to comprehensively evaluate the individual condition of patients and actively analyze the characteristics of the condition,forming a modern management system and optimization program to ensure the safety of patients'medication.